Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30265188 | 0.82 | POLB (0.60) | ALDH1A1CD274MAPK1 | |
| SCHEMBL30265334 | 0.80 | POLB (0.60) | ALDH1A1CD274MAPK1KDM4E | |
| SCHEMBL2350430 | 0.80 | POLB (0.60) | ALDH1A1CD274MAPK1KDM4E | |
| SCHEMBL30265074 | 0.76 | TSHR (0.58) | SMN1; SMN2ALDH1A1KDM4ETSHR | |
| SCHEMBL1436987 | 0.76 | ALDH1A1 (0.56) | SMN1; SMN2ALDH1A1LMNAKMT2ACD274 | |
| SCHEMBL3735019 | 0.75 | HTT (0.45) | SMN1; SMN2ALDH1A1LMNAKMT2AMAPK1 | |
| SCHEMBL28670109 | 0.74 | MAOB (0.68) | SMN1; SMN2ALDH1A1CD274 | |
| SCHEMBL5804723 | 0.73 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1KDM4ETSHR | |
| SCHEMBL7244316 | 0.73 | LMNA (0.57) | SMN1; SMN2ALDH1A1LMNAKMT2ACD274 | |
| SCHEMBL29834822 | 0.72 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1LMNAKMT2ACD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273890-B2 | Thiophene-imidazopyridines | 4SC AG (DE) | 2012-09-25 | — | — | US | disclosed |
| US-20100278833-A1 | THIOPHENE-IMIDAZOPYRIDINES | 4SC AG (DE) | 2010-11-04 | — | — | US | disclosed |
| EP-2017277-A1 | Thiophene-imidazopyridines | 4SC AG (DE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2009003911-A1 | THIOPHENE-IMIDAZOPYRIDINES | 4SC AG (DE) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278833-A1 | THIOPHENE-IMIDAZOPYRIDINES | PIKFYVE, PIP4K2B, PIP5K1B | SMN1; SMN2 2965/4885ALDH1A1 3695/4885LMNA 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.